Background/Aims: Aortic arch calcification (AoAC) is frequently detected in maintenance hemodialysis (MHD) patients and is associated with cardiovascular and all-cause mortality. We investigated the factors associated with AoAC and analyzed the relationship between the factors including bone-derived biomarkers and AoAC. Methods: We enrolled 389 stable MHD patients. AoAC was assessed using chest-X ray examination. Demographic data was collected in addition to serum levels of biochemical and bone-derived biomarkers, including sclerostin and fibroblast growth factor-23 (FGF-23). Results: Two hundred sixteen patients (55.5%) had AoAC. Patients with AoAC score ≥ 4 were older, with a higher percentage being male, and exhibited lower serum levels of albumin and triglyceride. Serum FGF-23 levels were inversely associated with AoAC severity, and FGF-23was directly related to vascular calcification. Age, gender, and dialysis vintage were independent predictors of AoAC. Conclusion: MHD patients have a high prevalence of AoAC. The grade of AoAC was dependent on older age in association with longer dialysis vintage. Levels of circulating FGF-23 but not sclerostin were related to AoAC severity. Serum FGF-23 levels were independently associated with AoAC.
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Introduction Cardiovascular disease is the major cause of death in patients undergoing maintenance hemodialysis (MHD) [1] . One of the major factors contributing to the markedly increased cardiovascular mortality and morbidity is vascular calcification in patients with end-stage renal disease (ESRD) [2] . Recently, vascular calcification in the coronary arteries and the aorta has been recognized as an important risk factor for cardiovascular disease in MHD patients [3] . Although vascular calcification is considered an aging process in nature, the presence of calcification in any arterial wall is associated with a three-to-four-fold higher risk of cardiovascular events and mortality [4] .
Noordzij et al. have demonstrated the association between the presence and extent of vascular calcification and outcome in the dialysis population [5] . The extent of vascular calcification can be quantified with electron beam computer tomography [6] and multidetector computer tomography [7] . Plain radiography is a convenient and inexpensive tool for the identification of vascular calcification. In the general population, aortic arch calcification (AoAC) identified in chest radiography has been shown to correlate with cardiovascular mortality in longitudinal follow-up periods [8] .
We have recently reported the validity and usefulness of assessment of AoAC grade, as determined by a simple chest X-ray [9, 10] . AoAC grade was significantly associated with a clustering of traditional risk factors. However, it is still unknown whether AoAC grade is a sensitive predictor of cardiovascular and all-cause mortality.
Sclerostin is synthetized by the osteocytes, and inhibits the bone anabolic Wnt pathway, which promotes bone formation [11] . It has already been shown that serum levels of sclerostin are elevated in hemodialysis patients, with an inverse correlation to serum parathyroid hormone (PTH) and bone formation rate [12] . In addition, Sabbagh et al. have recently detailed how an increased bone expression of sclerostin experimental models [13] , and probably plays a role in the pathophysiology of renal osteodystrophy, potentially increasing bone resistance to PTH. As a consequence, it would be expected that higher sclerostin is associated with worse outcomes. Surprisingly, it has recently been shown in HD patients that high circulating sclerostin levels are associated with improved survival instead [14] . Therefore, there is still some debate on whether circulating sclerostin could be a new biomarker of outcome. In addition, the potential relationship of serum sclerostin with another biomarkers, for example, fibroblast growth factor-23 (FGF-23) or recently described sclerostin modulators, such as inflammatory cytokines [15] , have not yet been evaluated.
To investigate these points, we conducted a cross-sectional study to analyze the factors that are associated with AoAC in MHD patients. We also measured circulating levels of bonederived biomarkers and determined their relationship with AoAC.
Materials and Methods

Study population
There were 402 stable MHD patients (dialysis duration > 6 months) at Jyoban Hospital Kidney Center, Fukushima, Japan, during July 2012; this constituted the study population. Of these, patients with acute illness, significant infection, or malignancy were excluded. Of the remaining patients, 389 patients (male/ female = 254/135, mean age 66.1 ± 12.9 years) provided their informed consent for evaluating a chest radiograph, as described next, and were thus investigated in the present study. The underlying causes of ESRD were diabetes (n = 178), chronic glomerulonephritis (n = 128), hypertensive nephropathy (n = 73), polycystic kidney (n = 6), and unknown etiology (n = 4). The enrolled patients underwent stable regular HD using bicarbonate dialysate. At baseline, a chest radiograph of each patient was obtained. They comprised a random sample of patients from the Kidney Center in Jyoban Hospital without a selection bias. This study was in compliance with the Declaration of Helsinki and was approved by the ethics review committee (No. 26-1) of Jyoban Hospital.
Assessment of AoAC
We performed a retrospective review of 389 patients undergoing dialysis therapy. Two radiologists (one specializing in chest radiography) independently reviewed all chest radiographs obtained from MHD patients studied. Radiographs were assessed for the presence of AoAC using a specific scale as previously described by Ogawa et al. [9] . The scale which was divided into sixteen circumferences was attached to the aortic arch on chest X-ray and then the number of sectors with calcification was divided by 16. Aortic arch calcification score (AoACS) was calculated after multiplication by 100 to express the results as a percentage. This value was used as the indicator of the AoAC. Our previous study confirmed that AoACS was highly correlated with AoAC volume evaluated by MSCT (r=0.635, p<0.001) [9] . The extent of AoAC was divided into four grades according to the following categorization. Group I, AoACS=0%; Group II, AoACS=1-3%; Group II, AoACS=4-12%.
Laboratory and hemodynamic measurements
Blood was drawn prior to initiating a dialysis session in a fasting state. Serum albumin, calcium, phosphate, total cholesterol, high-density lipoprotein (HDL) cholesterol, triglyceride, blood sugar, C-reactive protein (CRP) and the concentration of hemoglobin were measured by using routine laboratory methods.
The mean values of three measurements during the 3 months before chest radiography were used for analysis. Serum intact parathyroid hormone (PTH) was measured once at the time of radiography. Serum calcium levels were adjusted using the formula [calcium + (4-albumin)]. On the same day, blood samples were collected and frozen, while serum samples were stored for further analyses. Serum FGF-23 level was measured by sandwich-type enzyme-linked immunosorbent assay (ELISA) for human human FGF-23 (Kainos Laboratories Inc., Tokyo, Japan), which measures biological active, full-length FGF-23 using two monoclonal antibodies for FGF-23, as described previously [16, 17] . The intra-assay coefficient of variation of the measurement was <10%. Serum sclerostin level were measured by sandwich-type ELISA using commercial reagents (Biomedica Medizinprodukte, Vienna, Austria, as described previously [18] . The intraassay coefficient of variation of the measurement ranged from 5 -7%.
The clinical status of all subjects was evaluated by means of routine clinical examination before the regular HD session. Systolic and diastolic blood pressures (BPs) were measured with a mercury sphygmomanometer with the patient in the supine position after 10 to 15 minutes of rest, and the mean values for one month were used for the analysis. Hypertension was defined as: (a) predialysis systolic blood pressure greater than 140 mmHg, (b) diastolic blood pressure greater than 90 mmHg, or (c) if they were using any antihypertensive therapy.
Statistical analysis
Continuous variables were expressed as means ± SD and categorical variables as percentages. Spearman's correlation analysis, a nonparametric test, was used to assess the relationship among bonederived biomarkers, clinical and biochemical factors, and AoACS. All subjects were subsequently stratified into four groups, depending on the AoACS. In order to compare the different AoAC severity groups, the chi-square test was used for categorical variables and either the one-way analysis of variance (ANOVA) or the Kruskal Wallis test was utilized for the continuous variables featuring normal or skewed distribution, respectively. The levels of bone-derived biomarkers among the four groups were compared using the posthoc Bonferroni-corrected Mann-Whitney U test. Additionally, in order to explore the independent factors that are attributed to the AoACS, variables with a P < 0.1 in univariate linear regression analysis were selected for multiple linear regression analysis. Significant variables were then selected for further analysis using multivariate Cox proportional hazard models. All analyses were performed using JMP for Windows (version 11). A p-value of <0.05 was considered statistically significant.
Results
Baseline Characteristics of the Study Population
The mean age of the enrolled patients was 66.1 ± 12.9 years and female patients accounted for 34.7% of all subjects. The mean duration of dialysis therapy was 63.7 ± 74.4 months.
Hypertension and diabetes were noted in 72.4% and 45.8% of the study population, respectively. One hundred seventy-three subjects (44.5%) did not show evidence of AoAC.
Comparison of AoAC severity among groups
The results of the comparison of the different AoAC severity among patients are summarized in Table 1 . Patients without calcification were younger in addition to being less likely to be male, while groups with severe calcification had higher values of Kt/V, intact PTH and triglyceride, and lower albumin values. There were no significant differences in serum levels of calcium, phosphate and calcium phosphate products between the different groups. Furthermore, there was also no significant difference in bone-derived biomarkers such as sclerostin and FGF-23 and prescription of vitamin D and (Fig. 1a) , but not in serum sclerostin levels (Fig. 1b) . Interestingly, we found a decreasing trend in the serum FGF-23 levels with increasing AoAC severity. The BMI values, dialysis vintage, prevalence of diabetes, serum levels of calcium, phosphorous, alkaline phosphatase, and CRP were similar between the four groups.
Relationship between bone-derived biomarkers and AoAC
As shown in Fig. 2 , no significant relationship was observed between serum sclerostin and FGF-23 levels. With regard to other bone mineral metabolism parameters, serum sclerostin levels were positively associated with serum phosphorous (r = 0.115; P = 0.00324), calcium x phosphate products (r = 0.126; P = 0.0188), and negatively associated with serum iPTH levels (r = −0.210; P < 0.0001)). The serum FGF-23 levels had positive associations with calcium (r = 0.285, P < 0.0001), phosphorous (r = 0.382, P < 0.0001), calcium x phosphate products (r = 0.461, P < 0.0001), and iPTH (r = 0.117, P = 0.0297). There was a significant relationship between the serum levels of sclerostin and FGF-23 and prescription of phosphate binders. The serum FGF-23 levels (Fig. 3a) , but not sclerostin levels (Fig. 3b) , were negatively correlated AoACS. Table 2 shows the results of univariate and multivariate linear regression analysis of the AoACS. Age, gender, and dialysis vintage were independent predictors of AoACS. Unfortunately, serum 
Linear regression analysis of determinants of AoCC
Discussion
The results of this study revealed a high prevalence of AoAC in MHD patients, nearly 50% of whom, presented with advanced c a l c i f i c a t i o n . Furthermore, we found a decreasing trend in the serum FGF-23 as a bonederived biomarker with increasing AoAC severity. However, serum sclerostin and FGF-23 levels were not independent predictors for the severity of AoAC. Time on dialysis was another factor related to the grade of AoAC.
The classical vascular risk factors which showed independent association with the presence of vascular calcifications were age, dyslipidemia and diabetes, while age was the most significant factor [2] . With respect to dyslipidemia and diabetes, there was no significant association with AoAC in the multivariate model. Ajiro et al. [19] previously reported that older age in association with longer dialysis vintage was an independent mortality risk factor. With age, increased arterial stiffness associated with vascular calcification results in a selective elevation of pulse pressure caused by an increased systolic BP and a decrease of diastolic BP.
Vascular calcification has been considered a risk factor of cardiovascular mortality in ESRD patients. Arterial calcification increase stiffness and reduce elasticity of large arteries such as the aorta, which may result in substantial mortality and morbidity by impairing cardiovascular hemodynamics and vascular compliance [20] . The KDIGO clinical practice guideline recommends plain X-ray films of the lumbar spine for the detection and assessment of cardiovascular calcification in HD patients [21] . The AoAC identified in plain chest X-ray is associated with an increased risk of coronary artery disease and is linked to cardiovascular risk factors such as age, hypertension, dyslipidemia and diabetes mellitus in the general population [22, 23] . Moreover, compared with traditional risk factors, AoAC is an independent determinant of cardiovascular outcome [24] . However, the mechanism of AoAC progression remains unknown and requiring future investigations.
Vascular calcification is a dynamic process that results from an imbalance between promoters and inhibitors [25] . FGF-23 and Klotho have recently been recognized as contributors to ectopic calcification in soft tissues, including cardiac valves and the aorta [26, 27] . Irrespective of phosphorous levels, FGF-23 independently predicts survival chances of chronic HD patients [28, 29] . However, whether FGF-23 plays an active pathogenetic role in uremic vascular calcification remains uncertain, and experimental studies have exhibited opposing effects on the calcification process [30, 31] . Recently, there is growing evidence of the role of the Wnt-ß-catenin signaling pathway in vascular calcification. Martinez-Moreno et al. reported that activation of the Wnt/β-catenin signaling pathway enhances the phenotype switch and transformation of the vascular smooth cell into the osteoblast-like cell [32] . Moreover, sclerostin has been considered to be as an inhibitor of bone mineralization by suppressing Wnt signaling [33] . However, the relationship between sclerostin and vascular calcification is controversial when considering ESRD patients. Delanaye et al. found no association between sclerostin and the aortic calcification grade in HD patients [34] , whereas Pelletier el al. reported that sclerostin levels correlated with aortic calcification severity [35] . Lee et al. have recently revealed a strong association between aortic calcification score and sclerostin, with the level of sclerostin being independently associated with aortic calcification [36] . The results of the present study have shown no association between serum sclerostin and AoAC. The discrepancy might be attributed to the diversity in the study population and detection methods.
The prescription of active vitamin D and phosphate binders might have an influence on serum sclerostin and FGF-23 levels in MHD patients. Active vitamin D treatment has found to increase serum sclerostin levels in non-dialysis patients with chronic kidney disease (CKD) and such an effect is abolished by the adjustment of PTH, suggesting that it may serve to counter PTH suppression [37] . However, the percentage of active vitamin D and phosphate binder administration was not significantly different among the subjects divided by AoAC severity. Moreover, multivariate analyses showed that serum sclerostin and the prescription of active vitamin D and phosphate binders were not independent predictors for AoAC. Thus, the prescription of active vitamin D and phosphate binders are considered not to be major determinants of AoAC in MHD patients.
There are several limitations in the present study. First, the evaluation of AoAC is the semi-quantitative method, thus this method using four grades to evaluate AoAC is relatively crude. Therefore, the true calcium deposition in the aortic wall may be underestimated. However, our previous study confirmed that AoACS was highly correlated with aortic arch calcification volume evaluated by multi-slice CT [9] . Second, the interpretation of the data from our study is limited by the study design. Caution is necessary since this cross-sectional study only accounted for the associations between the biomarkers and vascular calcification, and did not examine the causal relationship between these factors. Third, it is still unknown whether AoAC grade is a sensitive predictor of cardiovascular and all-cause mortality. Finally, we describes a decreasing trend in serum FGF-23 levels with increasing AoAC. This result is conflicting with the majority of clinical studies reported in current literature. Usually, higher levels of FGF-23 are related to severity of vascular damage. We suspect a protective effect of FGF-23 on AoAC. Thus, incident longitudinal prospective studies are needed in order to determine whether sclerostin and FGF-23 truly contribute to calcification genesis and are implicated in clinical outcomes.
Conclusion
The results of the present study demonstrated the high prevalence of AoAC in MHD patients. The grade of AoAC was dependent on older age in association with longer dialysis vintage. Levels of circulating FGF-23 but not sclerostin levels were associated with the AoAC severity. Serum sclerostin and FGF-23 levels were not predictors for AoAC in these patients.
